Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

When is the best time to fix other blocked arteries after a heart attack?

NCT ID NCT07741721

Disease control Sponsor: Chonnam National University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 03, 2026 · Last updated Aug 18, 2026 · Updated 3 times

Summary

This trial is testing the best timing for opening additional blocked arteries in people who have had a severe type of heart attack (STEMI) with multiple blocked vessels. After the main blocked artery is opened, participants are randomly assigned to have the other blockages treated either during the same hospital stay or after discharge. The goal is to see which approach reduces the risk of death, another heart attack, or the need for further procedures.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Percutaneous coronary intervention (PCI) for non-infarct related arteries, performed either during the same hospital stay or after discharge
What this could lead to
If successful, this could establish the optimal timing for additional artery-opening procedures in heart attack patients, potentially reducing deaths, repeat heart attacks, and the need for further interventions.
What could go wrong
The trial is still recruiting and results are not yet available. The optimal timing may not significantly differ, and there are inherent risks of PCI, such as bleeding, vessel damage, or kidney injury from contrast dye.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,252 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jul 2035

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥19 years * ST-segment elevation myocardial infarction (STEMI): ST-segment elevation ≥ 0.1 mV in at least two contiguous leads, or New-onset left bundle branch block (LBBB) * Primary PCI within 12 h after symptom development * At least 1 non-infarct related artery (non-IRA) with diameter ≥ 2.5 mm and 50% stenosis by visual estimation Exclusion Criteria: * Cardiogenic shock at initial presentation or after infarct-related artery (IRA) treatment * Thrombolysis in myocardial infarction flow at non-IRA ≤ 2 * Severe procedural complications during primary percutaneous coronary intervention that, in the judgement of the operator, preclude study enrollment * Non-IRA lesion unsuitable for percutaneous coronary intervention (PCI) treatment that, in the judgement of the operator, preclude study enrollment * Chronic total occlusion in a non-IRA * History of anaphylaxis to contrast agent * Pregnancy and lactation * Life expectancy \< 1 year * Severe valvular heart disease * History of coronary artery bypass grafting (CABG) or planned CABG * Fibrinolysis therapy prior to admission * Severe asthma

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myocardial infarction (MI) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myocardial infarction ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myocardial infarction (MI)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    30 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ajou University Hospital

    Suwon, South Korea

  • Bucheon Sejong Hospital

    Bucheon-si, South Korea

  • Chonnam National University Hospital

    Gwangju, South Korea

  • Chosun University Hospital

    Gwangju, South Korea

  • Chung-Ang University Gwangmyeong Hospital

    Gwangmyeong, South Korea

  • Chungbuk National University Hospital

    Cheongju-si, South Korea

  • Chungnam National University Hospital

    Daejeon, South Korea

  • Daegu Catholic University Medical Center

    Daegu, South Korea

  • Gwangju Veterans Hospital

    Gwangju, South Korea

  • Gyeongsang National University Changwon Hospital

    Changwon, South Korea

  • Gyeongsang National University Hospital

    Jinju, South Korea

  • Inje University Busan Paik Hospital

    Pusan, South Korea

  • Inje University Haeundae Paik Hospital

    Pusan, South Korea

  • Jeju National University Hospital

    Jeju City, South Korea

  • Jeonbuk National University Hospital

    Jeonju, South Korea

  • Kangwon National University Hospital

    Chuncheon, South Korea

  • Keimyung University Dongsan Hospital

    Daegu, South Korea

  • Koera University Guro Hospital

    Seoul, South Korea

  • Korea University Anam Hospital

    Seoul, South Korea

  • Kosin University Gospel Hospital

    Pusan, South Korea

  • Kwangju Christian Hospital

    Gwangju, South Korea

  • Kyungpook National University Hospital

    Daegu, South Korea

  • Presbyterian Medical Center

    Jeonju, South Korea

  • Pusan National University Hospital

    Pusan, South Korea

  • Pusan National University Yangsan Hospital

    Yangsan, South Korea

  • Samsung Changwon Medical Center

    Changwon, South Korea

  • Soon Chun Hyang University Hospital Cheonan

    Cheonan, South Korea

  • St. Carollo General Hospital

    Suncheon, South Korea

  • Yeongnam University Medical Center

    Daegu, South Korea

  • Yonsei University Health System, Gangnam Severance Hospital

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.